News Sentiment

RNTX sentiment intelligence

Rein Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.98 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-1.2% over one week, +2.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support Level - McClellan Summation

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -1.2% Price digesting
Trend fit Trend inactive 2.3% over four weeks
Fair value -56.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
TradingKey 8
Market source 7
Stock Titan 4
GlobeNewswire 4
Investing.com 3
PR Newswire 3
DonanımHaber 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 16
Analyst action 5
Balance sheet 2
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
TradingView Direct company coverage

Price to sales forward of Rein Therapeutics, Inc. – NASDAQ:RNTX

The article provides a title indicating "Price to sales forward of Rein Therapeutics, Inc. – NASDAQ:RNTX" and appears to be a financial data page from TradingView. It lists the company, its Nasdaq stock market ticker, and general financial and market information categories. Howev

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 15:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Rein Therapeutics, Inc. – NASDAQ:RNTX

This article focuses on the enterprise value to revenue forward metric for Rein Therapeutics, Inc. (NASDAQ: RNTX). It appears to be a financial data point presented within a larger financial platform context, offering a snapshot of a specific valuation ratio for the company.

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 02:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Rein Therapeutics, Inc. – BOATS:RNTX

The article discusses the "Price to sales forward" metric for Rein Therapeutics, Inc. (RNTX) on the Blue Ocean Alternative Trade System (BOATS) platform. This financial data is provided by TradingView, indicating that the market for RNTX was closed with no trades recorded at the

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Rein Therapeutics, Inc. – BOATS:RNTX

The article focuses on the "Price to earnings forward" metric for Rein Therapeutics, Inc. (RNTX), listed on the Blue Ocean Alternative Trade System (BOATS). It presents a financial data point for the pharmaceutical company but does not offer any specific figures or analysis withi

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 13:10
Source
TradingView
Finviz Direct company coverage

RNTX - Rein Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filing information for Rein Therapeutics Inc. (RNTX), detailing its financial performance, key metrics like market capitalization and sales, and stock performance data. It includes various financial ratios, insider and institutional ownership

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 07:40
Source
Finviz
www.marketscreener.com Direct company coverage

Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index

Rein Therapeutics Inc. (NasdaqCM:RNTX) has been added to the Russell Microcap Value Benchmark Index. The biotechnology company, specializing in orphan pulmonary and fibrosis indications, saw its stock increase by 1.94%, with its share price trading at $0.9900. This news follows s

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 13:40
Source
www.marketscreener.com
TradingView Direct company coverage

RNTX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Rein Therapeutics, Inc. (RNTX) stock for 2027, based on analyst opinions. It highlights a maximum and minimum price target of $8.00 and includes financial data, recent stock performance, and answers frequently asked questions

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 15:09
Source
TradingView
TradingView Direct company coverage

Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX)

This article provides an overview of Rein Therapeutics, Inc. (NASDAQ: RNTX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, market capitalization, earnings per share, revenue, and other key financial data. The ar

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 15:09
Source
TradingView
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rein Therapeutics Inc (RNTX), highlighting its current valuation score and P/E ratio. The company's valuation score is 8.52, ranking it 118 out of 389 in the Biotechnology & Medical Research industry, with a P/E ratio of -0.48. Key va

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 13:11
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Institutional Confidence

Rein Therapeutics Inc's institutional shareholding score is 3.00, placing it at 193 out of 389 in the Biotechnology & Medical Research industry. The company's latest institutional shareholding proportion is 16.21%, a decrease of 51.20% quarter-over-quarter. James Simons is identi

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 13:11
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Rein Therapeutics Inc.'s (RNTX) financial health, noting its weak financial status and low operating efficiency with a score of 5.52, ranking 350 out of 389 in its industry. Key financial metrics such as cash and cash equivalents, total assets,

Tone
Negative 32/100
Event
Balance sheet
Published
19 Jun 2026 13:11
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Rein Therapeutics Inc (RNTX) currently holds an earnings forecast score of 7.00, placing it 316th out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $8.00 for RNTX, with a high of $10.00 and a low of $6.00, suggesting an upsi

Tone
Positive 69/100
Event
Earnings
Published
19 Jun 2026 00:10
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Rein Therapeutics Inc. (RNTX), highlighting that no specific risk assessment score is available for the company. It details various risk metrics such as volatility, maximum drawdown, and liquidity, and notes the company's beta value of

Tone
Neutral 50/100
Event
Balance sheet
Published
18 Jun 2026 19:09
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Rein Therapeutics Inc (RNTX), highlighting its major shareholders and institutional holdings. Voss Capital LLC is the largest reported shareholder, with significant institutional investment activity tracked over several quarters.

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 16:39
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rein Therapeutics Inc (RNTX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, RNTX's price momentum score is 6.70, with the stock trading betwee

Tone
Negative 39/100
Event
Market update
Published
17 Jun 2026 12:09
Source
TradingKey
TradingKey Direct company coverage

Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Rein Therapeutics Inc (RNTX). It notes that relevant data regarding business segments, regional revenue, and profit contribution for various fiscal years have not yet been disclosed by the company. The only specific in

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 17:09
Source
TradingKey
Investing.com Nigeria Direct company coverage

Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com

Rein Therapeutics announced that its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has enrolled 16 patients and randomized the first participant in the UK. The trial, which will evaluate the safety, tolerability, and efficacy of LTI-03, plans t

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 07:09
Source
Investing.com Nigeria
Market source Direct company coverage

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Rein Therapeutics announced the expansion of its Phase 2 RENEW clinical trial for LTI-03, an idiopathic pulmonary fibrosis treatment, into the United Kingdom, where the first patient has been randomized. The company has enrolled 16 patients to date, with clinical trial sites acti

Tone
Positive 73/100
Event
Market update
Published
12 Jun 2026 11:11
Source
Market source
Investing.com Direct company coverage

Rein Therapeutics enrolls 16 patients in lung fibrosis trial

Rein Therapeutics has announced that its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has enrolled 16 patients to date, with the first patient randomized in the UK. The trial expects to enroll about 120 patients across multiple countries to ev

Tone
Positive 66/100
Event
Guidance
Published
11 Jun 2026 12:09
Source
Investing.com
Stock Titan Direct company coverage

IPF trial for LTI-03 adds first UK patient, expands to 3 countries

Rein Therapeutics (NASDAQ: RNTX) announced that the first patient has been randomized in the United Kingdom for its Phase 2 RENEW clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), bringing the total enrollment to 16 patients across the US, Australia, and t

Tone
Positive 62/100
Event
Market update
Published
11 Jun 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay

Rein Therapeutics' 2026 proxy statement details key items for its virtual annual meeting on July 20, 2026, including the election of two Class III directors, a proposal to double authorized common shares from 100 million to 200 million, and the ratification of CBIZ CPAs P.C. as t

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 08:40
Source
Stock Titan
Investing.com Canada Direct company coverage

H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com

H.C. Wainwright has reduced its price target for Rein Therapeutics (NASDAQ:RNTX) shares from $10.00 to $8.00, while maintaining a Buy rating. This adjustment reflects the dilution caused by a recent $57.5 million common-stock financing, which addressed the company's liquidity con

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jun 2026 11:39
Source
Investing.com Canada
Finviz Direct company coverage

RNTX - Rein Therapeutics Inc Stock Price and Quote

This article provides detailed stock information for Rein Therapeutics Inc (RNTX), including its last close price, financial overview, key performance indicators, and recent news announcements. It also lists insider transactions and historical analyst ratings, offering a comprehe

Tone
Neutral 50/100
Event
Analyst action
Published
30 May 2026 04:41
Source
Finviz
Investing.com Direct company coverage

Rein Therapeutics director buys $49,560 in company stock

Josef H. von Rickenbach, a director at Rein Therapeutics, Inc. (NASDAQ:RNTX), recently purchased $49,560 worth of company stock through open market transactions in late May 2026. This acquisition, totaling 47,060 shares, occurred as the company's shares gained nearly 8% over the

Tone
Positive 69/100
Event
Deals and strategy
Published
29 May 2026 00:40
Source
Investing.com